CRISPR-Cas9 entra en acción

las tijeras moleculares que desafían al síndrome de Down

  • Beatriz Elena González Contreras Doctorado en Ciencias con Orientación en Medicina Molecular, Universidad Autónoma de Zacatecas, Zacatecas, México; Unidad de Investigación Biomédica de Zacatecas, Instituto Mexicano del Seguro Social, Zacatecas, México.
  • Virginia Flores Morales Ingeniería Química, Unidad Académica de Ciencias Químicas, Universidad Autónoma de Zacatecas, Zacatecas, México; Doctorado en Ciencias con Orientación en Medicina Molecular, Universidad Autónoma de Zacatecas, Zacatecas, México.
  • Carmen Judith Serrano Escobedo Unidad de Investigación Biomédica de Zacatecas, Instituto Mexicano del Seguro Social, Zacatecas, México
Keywords: Down Syndrome, Trisomy 21, CRISPR-Cas9, Gene editing

Abstract

Down syndrome is a genetic condition caused by an extra copy of chromosome 21, which affects the physical and cognitive development of those who have it. Although modifying this genetic cause remains a major challenge, experimental approaches are being explored to inactivate or eliminate the extra chromosome during the early stages of development. Recently, a group of scientists used stem cells derived from individuals with Down syndrome and applied the gene-editing tool CRISPR-Cas9 to selectively remove the extra copy of chromosome 21. This experimental intervention normalized the chromosome number in 37.5% of the treated cells, without affecting other chromosomes. This breakthrough opens the door to strategies that could enable intervention before birth to correct genetic alterations such as those seen in Down syndrome.

Downloads

Download data is not yet available.

References

Blanco-Montaño, A., Ramírez-Aguilar, M., Yáñez-Espinosa, B., Montaño-Sánchez, L., Ramírez-Cruz, A., Delgado-García, A., Martínez-Ramos, A., Martínez-Hernández, J., Aguilar-Sánchez, E., Aranda-Cortés, C. y Chávez-Castañeda, A., Risk factors in the origin of Down syndrome, Rev. Med. Inst. Mex. Seguro Soc., 61[5], pp.6638–6644, 2023.
Chen, M., Mao, A., Xu, M., Weng, Q., Mao, J. y Ji, J., CRISPR-Cas9 for cancer therapy: Opportunities and challenges, Cancer Lett., 447, pp.48–55, 2019. https://doi.org/10.1016/j.canlet.2019.01.017
Cleveland Clinic, Down Syndrome, Cleveland Clinic Health Library, https://my.clevelandclinic.org/health/diseases/17818-down-syndrome, 2023
Down Syndrome Achieves, Understanding the Three Different Types of Down Syndrome, Down Syndrome Achieves, https://dsachieves.org/2024/04/19/understanding-the-three-different-types-of-down-syndrome/#About%20Us%20N, 2024.
Hashizume, R., Wakita, S., Sawada, H., Takebayashi, S., Kitabatake, Y., Miyagawa, Y., Hirokawa, Y.S., Imai, H. y Kurahashi, H., Trisomic rescue via allele-specific multiple chromosome cleavage using CRISPR-Cas9 in trisomy 21 cells, PNAS Nexus, 4[2], 2025. https://doi.org/10.1093/pnasnexus/pgaf022
National Institute of Child Health and Human Development (NICHD), ¿Qué causa el síndrome de Down?, NICHD Español, https://espanol.nichd.nih.gov/salud/temas/down/informacion/causas, 2012.
Published
2026-06-30
How to Cite
González Contreras , B. E., Flores Morales, V., & Serrano Escobedo , C. J. (2026). CRISPR-Cas9 entra en acción: las tijeras moleculares que desafían al síndrome de Down. Contactos, Revista De Educación En Ciencias E Ingeniería, (146), 18 - 25. Retrieved from https://contactos.izt.uam.mx/index.php/contactos/article/view/685
Section
Artículos